This “Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Spleen tyrosine kinase inhibitors Understanding
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk inhibitors are a new group of small molecule inhibitors targeting BCR-mediated signaling pathways.
Syk was recognized as a critical element in the BCR signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk along with other BCR signaling molecules, Bruton tyrosine kinase (BTK), PI3K delta (PI3Kδ), and tumor necrosis factor (TNF) superfamily receptors was also found to be involved in signal transduction independent from the BCR. Syk is expressed primarily in hematopoietic cells like B-cells, monocytes, macrophages, mast cells, and neutrophils. Syk was recognized to be a potential target for the treatment of various hematologic cancers, autoimmune disorders, and other inflammatory states.
Report Highlights
This segment of the Spleen tyrosine kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spleen tyrosine kinase inhibitors Emerging Drugs
Fostamatinib: Rigel Pharmaceuticals
Fostamatinib is a selective, oral spleen tyrosine kinase (SYK) inhibitor being evaluated for Autoimmune haemolytic anaemia, COVID-19 which is currently in Phase III stage of development and is being developed by Rigel Pharmaceuticals.
Entospletinib: Kronos Bio
Entospletinib (ENTO), is a selective inhibitor targeting SYK, a critical node in a dysregulated TRN within AML defined by persistent high expression of the transcription factors HOXA9 and MEIS1 (HOX/MEIS). It is currently in Phase II stage of development for the treatment of Acute myeloid leukaemia and is being developed by Kronos Bio.
This segment of the report provides insights about the different Spleen tyrosine kinase inhibitors drugs segregated based on following parameters that define the scope of the report.
There are approx. 10+ key companies which are developing the Spleen tyrosine kinase inhibitors. The companies which have their Spleen tyrosine kinase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Rigel Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Spleen tyrosine kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Spleen tyrosine kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen tyrosine kinase inhibitors drugs.
Geography Covered
- Global coverage
Spleen tyrosine kinase inhibitors Understanding
Spleen tyrosine kinase inhibitors: Overview
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk inhibitors are a new group of small molecule inhibitors targeting BCR-mediated signaling pathways.
Syk was recognized as a critical element in the BCR signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk along with other BCR signaling molecules, Bruton tyrosine kinase (BTK), PI3K delta (PI3Kδ), and tumor necrosis factor (TNF) superfamily receptors was also found to be involved in signal transduction independent from the BCR. Syk is expressed primarily in hematopoietic cells like B-cells, monocytes, macrophages, mast cells, and neutrophils. Syk was recognized to be a potential target for the treatment of various hematologic cancers, autoimmune disorders, and other inflammatory states.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spleen tyrosine kinase inhibitors R&D. The therapies under development are focused on novel approaches for Spleen tyrosine kinase inhibitors.
Spleen tyrosine kinase inhibitors Emerging Drugs Chapters
This segment of the Spleen tyrosine kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spleen tyrosine kinase inhibitors Emerging Drugs
Fostamatinib: Rigel Pharmaceuticals
Fostamatinib is a selective, oral spleen tyrosine kinase (SYK) inhibitor being evaluated for Autoimmune haemolytic anaemia, COVID-19 which is currently in Phase III stage of development and is being developed by Rigel Pharmaceuticals.
Entospletinib: Kronos Bio
Entospletinib (ENTO), is a selective inhibitor targeting SYK, a critical node in a dysregulated TRN within AML defined by persistent high expression of the transcription factors HOXA9 and MEIS1 (HOX/MEIS). It is currently in Phase II stage of development for the treatment of Acute myeloid leukaemia and is being developed by Kronos Bio.
Spleen tyrosine kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Spleen tyrosine kinase inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players working on Spleen tyrosine kinase inhibitors
There are approx. 10+ key companies which are developing the Spleen tyrosine kinase inhibitors. The companies which have their Spleen tyrosine kinase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Rigel Pharmaceuticals.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Spleen tyrosine kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Spleen tyrosine kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Spleen tyrosine kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen tyrosine kinase inhibitors drugs.
Spleen tyrosine kinase inhibitors Report Insights
- Spleen tyrosine kinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Spleen tyrosine kinase inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing Spleen tyrosine kinase inhibitors drugs?
- How many Spleen tyrosine kinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Spleen tyrosine kinase inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spleen tyrosine kinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spleen tyrosine kinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Dermavant Sciences
- Rigel Pharmaceuticals
- Kronos Bio
- Hutchison MediPharma
- Hanmi Pharmaceutical
- Genosco
- Asana BioSciences
Key Products
- Cerdulatinib
- Fostamatinib
- Entospletinib
- Lanraplenib
- HMPL-523
- HM43239
- SKI O 703
- ASN002
Table of Contents
IntroductionExecutive Summary
Spleen tyrosine kinase inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Fostamatinib: Rigel Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Entospletinib: Kronos Bio
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
HM43239: Hanmi Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Spleen tyrosine kinase inhibitors Key Companies
Spleen tyrosine kinase inhibitors Key Products
Spleen tyrosine kinase inhibitors- Unmet Needs
Spleen tyrosine kinase inhibitors- Market Drivers and Barriers
Spleen tyrosine kinase inhibitors- Future Perspectives and Conclusion
Spleen tyrosine kinase inhibitors Analyst Views
Spleen tyrosine kinase inhibitors Key Companies
AppendixList of Tables
Table 1 Total Products for Spleen tyrosine kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Spleen tyrosine kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Dermavant Sciences
- Rigel Pharmaceuticals
- Kronos Bio
- Hutchison MediPharma
- Hanmi Pharmaceutical
- Genosco
- Asana BioSciences
